The available data on adjuvant safety and efficacy have mostly been generated using a wide variety of protocols, model systems and individual approaches, which makes it difficult or impossible to ...

Regulatory guidelines for new adjuvants licensure are still being formulated with the main concern based on the safety of the vaccines. Although current regulations focus on traditional adjuvants ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

Because patients had already completed treatment at the time of the primary analysis, safety data at this update were as expected, and delayed toxic effects were rarely observed with adjuvant T-DM1.

Diverse Applications: Adjuvants improve the efficacy of a wide range of vaccines, including those for influenza, hepatitis, and HPV, ensuring optimal immune responses. Safety and Regulatory ...

The ultimate goal is to design novel adjuvants with enhanced safety and efficacy by leveraging a thorough understanding of ...